HPTN Publications

El-Bassel N, Shoptaw S, Skalland T, Hanscom B, Clarke W, Marzinke MA, Fogel JM, Richardson P, Choudhury RP, Denis C, Goodman-Meza D, Kuo I, Lake JE, Morrison EAB, Richards AM, Harris-Wisecarver J, Cummings M, Chandler R, Andrew P, HPTN 094 Study Team . Prevalence of Illicit Drug Detection in 5 US Cities Among Out-of-Treatment People Who Inject Drugs. JAMA. 2026, 9: e2555882

El-Diwany R, Breitwieser FP, Soliman M, Skaist AM, Srikrishna G, Blankson JN, Ray SC, Wheelan SJ, Thomas DL, Balagopal A . Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals. AIDS. 2017, 31: 1405-1414

El-Sadr WM, Affrunti M, Gamble T, Zerbe A . Antiretroviral therapy: a promising HIV prevention strategy?. J Acquir Immune Defic Syndr. 2010, 55: 116-21

El-Sadr WM, Beauchamp G, Hall IH, Torian LV, Zingman BS, Lum G, Elion RA, Buchacz K, Burns D, Zerbe A, Gamble T, Donnell D, for the HPTN 065 Study Team . Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care. JAIDS.

El-Sadr WM, Serwadda DM, Sista N, Cohen MS . HIV prevention: great achievements, more challenges ahead. J Acquir Immune Defic Syndr. 2013, 63: S115-6

Elbur AI, Donnell D, Hosek S, Dye B, Velloza J, Delany-Moretlwe S, Celum C . The Association Between Use of Adherence Support Interventions and Adherence to HIV Preexposure Prophylaxis Among Young South African and Zimbabwean Women in HPTN 082. AIDS Behav. 2025, 29: 2483-2494

Emory JF, Seserko LA, Marzinke MA . Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Clin Chim Acta. 2014, Apr 20: 198-205

Eshleman SH, Fogel JM, Halvas EK, Piwowar-Manning E, Marzinke MA, Kofron R, Wang Z, Mellors J, McCauley M, Rinehart AR, Clair MS, Adeyeye A, Hinojosa JC, Cabello R, Middelkoop K, Hanscom B, Cohen MS, Grinsztejn B, Landovitz RJ, HPTN 083 Study Team . HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention. J Infect Dis.